InvestorsHub Logo
Followers 87
Posts 6553
Boards Moderated 1
Alias Born 09/18/2009

Re: fireopal post# 7362

Tuesday, 09/19/2017 4:28:40 PM

Tuesday, September 19, 2017 4:28:40 PM

Post# of 42465
I'm surprised that the stock is holding at these levels. I suspect that, even though the FDA granted the Priority Review Voucher to a competitor, there is still value in Humanigen's development program. A Form D filing for officers and directors made a week AFTER the PRV was awarded to a competitor? And Jester coming on board at the same time, with a salary of $290k, and a disclaimer that he "..has no material interest in any transaction or proposed transaction in which the Company is or is to be a party." Maybe that's just boilerplate, but, altogether, it's still interesting.